Cognitive dysfunction and antiphospholipid antibodies in systemic lupus erythematosus

Area of Science:

• Neurology
• Immunology
• Rheumatology

Background:

• Systemic lupus erythematosus (SLE) frequently affects the nervous system, presenting as neuropsychiatric lupus erythematosus (NPSLE).
• Clinical diagnosis of NPSLE relies on neurological and psychiatric syndromes, but nervous system integrity can be assessed using neuropsychological tests.
• Cognitive dysfunction is a recognized manifestation of NPSLE, occurring across a spectrum of severity.

Purpose of the Study:

• To evaluate the prevalence and nature of cognitive dysfunction in SLE patients.
• To explore potential pathogenetic mechanisms underlying cognitive deficits in NPSLE.
• To highlight the role of antiphospholipid antibodies in NPSLE.

Main Methods:

• Application of neuropsychological tests to assess cognitive function in SLE patients.
• Analysis of clinical data to correlate cognitive status with neurological and psychiatric syndromes.
• Investigation of potential etiological factors, including antibrain antibodies, proinflammatory cytokines, and antiphospholipid antibodies.

Main Results:

• Significant cognitive dysfunction was detected in a substantial proportion of SLE patients, irrespective of overt clinical NPSLE.
• The observed cognitive deficits exhibited heterogeneity, mirroring the diversity of clinical NPSLE manifestations.
• Antiphospholipid antibodies emerged as a robustly identified factor associated with cognitive dysfunction in SLE.

Conclusions:

• Cognitive dysfunction is a prevalent and accepted manifestation of NPSLE, detectable even without major clinical syndromes.
• The pathogenesis of cognitive deficits in NPSLE is multifactorial, with varying degrees of evidence for different mechanisms.
• Antiphospholipid antibodies represent a significant pathogenetic factor in NPSLE with potential therapeutic implications.